Evolent Health (NYSE:EVH) Reaches New 1-Year Low - Here's Why

Evolent Health, Inc. (NYSE:EVH - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $9.55 and last traded at $9.87, with a volume of 1535148 shares. The stock had previously closed at $9.94.

Analysts Set New Price Targets

Several research firms have recently weighed in on EVH. Citigroup decreased their price objective on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a report on Friday, January 10th. Oppenheimer lowered their target price on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a report on Friday, January 24th. Stephens decreased their price target on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. JMP Securities reissued a "market outperform" rating and issued a $12.00 target price on shares of Evolent Health in a research note on Friday. Finally, UBS Group cut their price target on shares of Evolent Health from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, January 16th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $17.92.

Evolent Health Stock Up 1.0 %

The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -11.06 and a beta of 1.45. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm has a 50 day moving average price of $10.86 and a 200-day moving average price of $19.24.

Institutional Investors Weigh In On Evolent Health

A number of institutional investors have recently made changes to their positions in the company. Creative Planning grew its stake in Evolent Health by 12.2% during the 2nd quarter. Creative Planning now owns 18,091 shares of the technology company's stock worth $346,000 after buying an additional 1,973 shares during the last quarter. GAMMA Investing LLC grew its stake in Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after buying an additional 1,556 shares during the last quarter. Friedenthal Financial bought a new position in Evolent Health during the 3rd quarter worth $723,000. Moody Aldrich Partners LLC bought a new position in Evolent Health during the 3rd quarter worth $1,421,000. Finally, Values First Advisors Inc. grew its stake in Evolent Health by 21.0% during the 3rd quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company's stock worth $909,000 after buying an additional 5,583 shares during the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.